FDA Approved: BYOOVIZ — Supplemental Application (BIOGEN INC.)

View source ↗

Summary

The FDA approved a supplemental application for BYOOVIZ (ranibizumab-nuna) from Biogen, authorizing its use as a biosimilar to ranibizumab.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Branch Retinal Vein Occlusion
• Central Retinal Vein Occlusion
• Diabetic Macular Edema
• Myopic Choroidal Neovascularization
• Neovascular Age-related Macular Degeneration

Drugs mentioned

• BYOOVIZ (ranibizumab-nuna)

Snippet

SUPPL AP for BYOOVIZ (RANIBIZUMAB-NUNA)